Metoprolol
Metoprolol is a beta-adrenergic blocker. The US label read, for Lopressor Oral Solution (metoprolol tartrate, a liquid taken by mouth), says it is indicated in adult patients for hypertension, to lower blood pressure; for the long-term treatment of angina pectoris; and, in hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.
Also called Lopressor
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 6918; UNII W5S57Y3A5L. The label names the substance as metoprolol tartrate, so UNII W5S57Y3A5L is the UNII of the tartrate salt and is a broad match. MeSH descriptor D008790 is Metoprolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Validus Pharmaceuticals LLC label for LOPRESSOR Oral Solution (metoprolol tartrate), application NDA219373, effective 2025-05-15 in openFDA. Other metoprolol labels in openFDA, including the LOPRESSOR tablet label and extended-release succinate products, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 11
- Phase 3 or 4
- 9
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 0 | 2 | 0 | 0 | 2 |
| Phase 3 | 1 | 1 | 0 | 0 | 2 |
| Phase 4 | 0 | 5 | 1 | 1 | 7 |
| All phases | 1 | 8 | 1 | 1 | 11 |
Conditions these trials study
- Hypertension (high blood pressure)
- Cardiomyopathy (heart muscle disease)
- Heart failure
- Acute coronary syndrome
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Coronary artery disease
- Diabetes mellitus
- Heart attack (myocardial infarction)
- Heart failure with mildly reduced or preserved ejection fraction
Sponsors with the most trials
- Asker & Baerum Hospital
- Braveheart Bio, Inc.
- Federico II University
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
- Merck KGaA, Darmstadt, Germany
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
W5S57Y3A5L
Claims and evidence
Context Adults for whom the US label of metoprolol (Lopressor Oral Solution) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction
- Recipient
- Adult
- Population
- Patients described in the indications section of the label, which says the medicine is indicated in adult patients.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passage read states
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adult patients with hypertension
- Adult patients needing long-term treatment of angina pectoris
- Hemodynamically stable adult patients with definite or suspected acute myocardial infarction
- Excluded
- None stated
The US label of LOPRESSOR Oral Solution (metoprolol tartrate), in the Validus Pharmaceuticals LLC version dated 2025-05-15 in openFDA, lists the medicine, in adult patients, for the treatment of hypertension, to lower blood pressure; for the long-term treatment of angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-05-15
- Source state
- Current
- Version fingerprint
25523029411d76fb5b7bd58d2ed1c4d5df2146c6fea9ccb8c83dccf569e19758- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250515.
- Retrieved
- Source effective date
- 2025-05-15
- Source state
- Current
- Version fingerprint
25523029411d76fb5b7bd58d2ed1c4d5df2146c6fea9ccb8c83dccf569e19758- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
DUTOPROL
No label from the application holder was found in the openFDA label dataset for application NDA021956. This page does not show another labeler's label in its place.
KAPSPARGO SPRINKLE
No label from the application holder was found in the openFDA label dataset for application NDA210428. This page does not show another labeler's label in its place.
LOPRESSOR
No label from the application holder was found in the openFDA label dataset for application NDA017963. This page does not show another labeler's label in its place.
LOPRESSOR
No label from the application holder was found in the openFDA label dataset for application NDA018704. This page does not show another labeler's label in its place.
LOPRESSOR
No label from the application holder was found in the openFDA label dataset for application NDA019786. This page does not show another labeler's label in its place.
LOPRESSOR
No label from the application holder was found in the openFDA label dataset for application NDA218698. This page does not show another labeler's label in its place.
LOPRESSOR
No label from the application holder was found in the openFDA label dataset for application NDA219373. This page does not show another labeler's label in its place.
LOPRESSOR HCT
No label from the application holder was found in the openFDA label dataset for application NDA018303. This page does not show another labeler's label in its place.
TOPROL-XL
No label from the application holder was found in the openFDA label dataset for application NDA019962. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA017963 - Supplemental approval
NDA017963 - Supplemental approval
NDA017963 - Approval
NDA018704 - Approval
NDA018303 - Supplemental approval
NDA017963 - Approval
NDA019786 - Approval
NDA019962 - Supplemental approval
NDA019962 - Supplemental approval
NDA019962 - Approval
NDA021956 - Supplemental approval
NDA019962 - Approval
NDA210428 - Approval
NDA219373 - Approval
NDA218698
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
The US label of LOPRESSOR Oral Solution (metoprolol tartrate), in the Validus Pharmaceuticals LLC version dated 2025-05-15 in openFDA, lists the medicine, in adult patients, for the treatment of hypertension, to lower blood pressure; for the long-term treatment of angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing cardiovascular mortality in stable patients with definite or suspected acute myocardial infarction as an indication: Heart attack (myocardial infarction)
The US label of LOPRESSOR Oral Solution (metoprolol tartrate), in the Validus Pharmaceuticals LLC version dated 2025-05-15 in openFDA, lists the medicine, in adult patients, for the treatment of hypertension, to lower blood pressure; for the long-term treatment of angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 9
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 11
Record details
- Record id
cardio:metoprolol- Content hash
aa8bbf44c67d4e7ce15a63469149fd7e1b5855e3daadaaec1ddf97a3658c76a5